Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia.
Norkin M, Katragadda L, Zou F, Xiong S, Chang M, Dai Y, Hsu JW, Moreb JS, Leather H, Murthy HS, Farhadfar N, Li Y, Hromas R, Brown RA, Cogle CR, Wingard JR. Norkin M, et al. Among authors: moreb js. Blood Cancer J. 2017 Nov 27;7(12):634. doi: 10.1038/s41408-017-0007-x. Blood Cancer J. 2017. PMID: 29176662 Free PMC article.
Effect of melphalan 140 mg/m(2) vs 200 mg/m(2) on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation-a single center experience.
Katragadda L, McCullough LM, Dai Y, Hsu J, Byrne M, Hiemenz J, May S, Cogle CR, Norkin M, Brown RA, Wingard JR, Chang M, Moreb JS. Katragadda L, et al. Among authors: moreb js. Clin Transplant. 2016 Aug;30(8):894-900. doi: 10.1111/ctr.12762. Epub 2016 Jun 29. Clin Transplant. 2016. PMID: 27219740
A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients.
Drusbosky LM, Singh NK, Hawkins KE, Salan C, Turcotte M, Wise EA, Meacham A, Vijay V, Anderson GG, Kim CC, Radhakrishnan S, Ullal Y, Talawdekar A, Sikora H, Nair P, Khanna-Gupta A, Abbasi T, Vali S, Guha S, Farhadfar N, Murthy HS, Horn BN, Leather HL, Castillo P, Tucker C, Cline C, Pettiford L, Lamba JK, Moreb JS, Brown RA, Norkin M, Hiemenz JW, Hsu JW, Slayton WB, Wingard JR, Cogle CR. Drusbosky LM, et al. Among authors: moreb js. Blood Adv. 2019 Jun 25;3(12):1837-1847. doi: 10.1182/bloodadvances.2018028316. Blood Adv. 2019. PMID: 31208955 Free PMC article. Clinical Trial.
Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levels.
Mainwaring MG, Rimsza LM, Chen SF, Gomez SP, Weeks FW, Reddy V, Lynch J, May WS, Kahn S, Moreb J, Leather H, Braylan R, Rowe TC, Fieniewicz KJ, Wingard JR. Mainwaring MG, et al. Leuk Lymphoma. 2002 May;43(5):989-99. doi: 10.1080/10428190290021339. Leuk Lymphoma. 2002. PMID: 12148910 Clinical Trial.
147 results